Børneergoterapien.dk ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  20.1% 25.4% 19.2% 11.6% 25.7%  
Credit score (0-100)  5 2 6 20 3  
Credit rating  B B B BB B  
Credit limit (kDKK)  -0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Net sales  0 0 0 0 0  
Gross profit  -53.9 444 616 306 1,133  
EBITDA  -183 180 60.2 -51.4 213  
EBIT  -183 180 60.2 -51.4 201  
Pre-tax profit (PTP)  -185.1 177.3 59.0 -51.6 201.1  
Net earnings  -185.1 178.6 45.3 -41.3 156.0  
Pre-tax profit without non-rec. items  -185 177 59.0 -51.6 201  

 
See the entire income statement

Balance sheet (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Tangible assets total  0.0 0.0 0.0 0.0 128  
Shareholders equity total  -145 33.5 78.9 37.6 194  
Interest-bearing liabilities  141 2.6 15.5 31.3 0.4  
Balance sheet total (assets)  51.6 131 127 119 269  

Net Debt  140 -14.6 15.5 7.9 -47.2  
 
See the entire balance sheet

Volume 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  -53.9 444 616 306 1,133  
Gross profit growth  0.0% 0.0% 38.8% -50.4% 270.6%  
Employees  1 1 1 1 1  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  52 131 127 119 269  
Balance sheet change%  0.0% 154.6% -3.3% -6.4% 126.1%  
Added value  -183.1 180.2 60.2 -51.4 212.9  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 116  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -1.0 1.0 2.0 -1.0 1.0  

Profitability 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  339.9% 40.6% 9.8% -16.8% 17.8%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  -93.1% 109.9% 46.6% -41.8% 103.9%  
ROI %  -129.5% 203.0% 92.2% -63.0% 138.4%  
ROE %  -358.8% 419.8% 80.7% -71.0% 135.0%  

Solidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Equity ratio %  -73.8% 25.5% 62.1% 31.6% 72.0%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -76.5% -8.1% 25.7% -15.4% -22.1%  
Gearing %  -97.4% 7.8% 19.6% 83.4% 0.2%  
Net interest  0 0 0 0 0  
Financing costs %  2.9% 4.1% 13.0% 0.8% 2.2%  

Liquidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Quick Ratio  0.3 1.3 2.6 1.5 3.0  
Current Ratio  0.3 1.3 2.6 1.5 3.0  
Cash and cash equivalent  1.3 17.2 0.0 23.4 47.6  

Capital use efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  -145.1 33.5 78.9 37.6 93.9  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales / employee  0 0 0 0 0  
Added value / employee  -183 180 60 -51 213  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  -183 180 60 -51 213  
EBIT / employee  -183 180 60 -51 201  
Net earnings / employee  -185 179 45 -41 156